Adaptimmune Therapeutics

Adaptimmune Therapeutics Plc engages in the development of novel cancer immunotherapy products. Its specific peptide enhanced affinity receptor platform enables the engineering of T-cells to target and destroy cancer, including solid tumors. The company was founded by Bent K. Jakobsen, James Julian Noble, and Helena Katrina Tayton-Martin in 2008 and is headquartered in Abingdon, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Adaptimmune reports strong Q1 results, eyes market leadership with afami-cel

Adaptimmune Therapeutics shows strong performance and progress in Q1 2024.
Strengths lie in innovative therapies, financial stability, and clear development plans.
Challenges include managing debt impact, FDA processes, and successful product launches.
Opportunities exist in market leadership, upcoming presentations, and growth strategies.

Adaptimmune achieves commercial milestone with Tecelra launch, poised for growth

Adaptimmune's Q2 performance reflects a transformative phase as it transitions into a commercial-stage company with a strong financial position and a focus on innovative cell therapies.
While facing challenges in operational execution and revenue forecasting, the company's strategic strengths lie in its pioneering treatments, robust pipeline, and customer-centric approach.
By capitalizing on opportunities for market expansion, strategic partnerships, and operational optimization, Adaptimmune is poised to drive growth and establish itself as a key player in the cell therapy sector.

Adaptimmune targets breakeven by 2027 with strong sarcoma franchise

Adaptimmune Therapeutics is strategically positioned to achieve operating breakeven by 2027 through significant cost reductions and a focus on their sarcoma franchise with Tecelra and lete-cel.
The company's financial stability, positive trial results, and revenue targets indicate a strong growth trajectory and confidence in their business strategy.
While facing challenges in cost reduction and workforce restructuring, Adaptimmune Therapeutics has opportunities to capitalize on market expansion and product efficacy to drive future growth.
Overall, the company's performance in Q3 reflects a proactive approach to financial sustainability and market competitiveness in the oncology sector.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Adaptimmune Therapeutics Plc is commercial-stage cell therapy company, which focuses on providing novel cell therapies to people with cancer. Its clinical pipeline includes Afami-cel, Lete-cel, and ADP-A2M4CD8. The company was founded by Bent K. Jakobsen, James Julian Noble, and Helena Katrina Tayton-Martin in 2008 and is headquartered in Abingdon, the United Kingdom.

Adaptimmune's Data In Treating Solid Tumors Reinforces Prior Data And Highlights Technology Platform

PHILADELPHIA, Pa. and OXFORD, United Kingdom, Jan.  24, 2020  (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (“Adaptimmune”)(Nasdaq: ADAP), a leader in T-cell therapy to treat cancer, today announced the closing of its previously announced underwritten public offering of its American Depositary Shares (“ADSs”).  Adaptimmune sold 21,000,000 ADSs at a price to the public of $4.00 per ADS.  Adaptimmune has also granted the underwriters a 30-day option to purchase up to 3,150,000 additional ADSs at the public offering price.

Adaptimmune Therapeutics  plc Announces Closing of Public Offering of American Depositary Shares

PHILADELPHIA and OXFORD, United Kingdom, Jan.  22, 2020  (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (“Adaptimmune”)(Nasdaq: ADAP), a leader in T-cell therapy to treat cancer, today announced the pricing of an underwritten public offering of 21,000,000 of its American Depositary Shares (“ADSs”) at a price to the public of $4.00 per ADS. In connection with the offering, Adaptimmune has granted the underwriters a 30-day option to purchase up to an additional 3,150,000 ADSs at the public offering price. The gross offering size for this offering is expected to be approximately $84.0 million, excluding any exercise of the underwriters' option to purchase additional ADSs. All ADSs in this offering are being sold by Adaptimmune with net proceeds to be used to advance the development of Adaptimmune’s immunotherapies into and through clinical trials as well as for other general corporate purposes. This offering is expected to close on or about January 24, 2020, subject to customary closing conditions.

Adaptimmune Therapeutics plc  Prices Public Offering of American Depositary Shares

Apple

Assetmark Financial Holdings Inc

Cardlytics

Top Ranked Momentum Stocks to Buy for January 22nd

PHILADELPHIA, Pa. and OXFORD, UK, Jan.  21, 2020  (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq: ADAP), a leader in T-cell therapy to treat cancer, today announced that it intends to offer and sell American Depositary Shares (“ADSs”) in an underwritten public offering. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Adaptimmune also expects to grant the underwriters a 30-day option to purchase additional ADSs at the public offering price. All of the ADSs in the offering are to be sold by Adaptimmune, with net proceeds to be used to advance the development of Adaptimmune’s immunotherapies into and through clinical trials as well as for other general corporate purposes.

Adaptimmune Therapeutics plc  Proposes Public Offering of American Depositary Shares

Aquestive Therapeutics Inc

BioNTech SE

Dare Bioscience

Nektar Therapeutics

Neon Therapeutics

As the biotechnology group is pushing near all-time highs, this past week played host to a huge number of biotech movers.

This Week’s Biggest Biotech Movers

Adaptimmune Therapeutics PLC (ADAP) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

What Makes Adaptimmune Therapeutics PLC (ADAP) a New Buy Stock

The clinical-stage company has inked a new deal with a big biopharma.

Why Adaptimmune Therapeutics Is Jumping 11.5% Today

- Agreement covers the co-development and co-commercialization of up to three T-cell therapies -

Astellas and Adaptimmune Enter into Agreement to Co-Develop and Co-Commercialize Stem-Cell Derived Allogeneic CAR-T and TCR T-Cell Therapies

Shares of smid-cap biotech Adaptimmune Therapeutics PLC – ADR (NASDAQ: ADAP) were skyrocketing Monday following a presentation at the 38th JPMorgan Healthcare Conference.

Adaptimmune Soars 250% On Positive Initial Responses For T-Cell Platform In 4 Tumor Types

Adaptimmune Therapeutics PLC (NASDAQ: ADAP) shares absolutely exploded on Monday after the company announced encouraging responses for its Spear T-cell platform.

This T-Cell Therapy Could Be a Game Changer for Adaptimmune

Organizational changes strengthen scientific and clinical development from early to late stage, and accelerate application of translational science learnings to therapeutic candidates and trials Organizational changes strengthen scientific and clinical development from early to late stage, and accelerate application of translational science learnings to therapeutic candidates and trials

Adaptimmune Appoints Elliot Norry as Chief Medical Officer and Makes Changes to R&D Leadership

- Partial Responses seen in liver, melanoma, gastro-esophageal junction, and head and neck cancers -

Adaptimmune Announces that SPEAR T-cell Platform Delivers Initial Responses in Four Solid Tumor Indications

Will enable expedited development and review of ADP-A2M4 with the goal of commercialization in 2022 for patients with few other treatment options Will enable expedited development and review of ADP-A2M4 with the goal of commercialization in 2022 for patients with few other treatment options

Regenerative Medicine Advanced Therapy Designation Granted by FDA to ADP‑A2M4 for the Treatment of Synovial Sarcoma

- Clinical responses in seven out of 14 patients with synovial sarcoma by RECIST 1.1 -

Updated Data from Phase 1 ADP-A2M4 Trial Demonstrating Continued Clinical Benefit for People with Synovial Sarcoma

Adaptimmune Therapeutics PLC (NASDAQ:ADAP) Q3 2019 Earnings Conference Call November 6, 2019 8:00 AM ET

Adaptimmune Therapeutics PLC (ADAP) CEO Adrian Rawcliffe on Q3 2019 Results - Earnings Call Transcript

Key step toward commercial-readiness for ADP-A2M4 therapy with launch planned for 2022 Key step toward commercial-readiness for ADP-A2M4 therapy with launch planned for 2022

Adaptimmune and Cryoport Announce Agreement to Ensure Safe and Fully Monitored Transport of Adaptimmune’s Cell Therapies

Adaptimmune Therapeutics (ADAP) gets Orphan Drug Designation for SPEAR T-cells targeting MAGE-A4 (ADP-A2M4 program) for the treatment of soft tissue sarcomas.

Adaptimmune (ADAP) Gets Orphan Drug Status for T-cell Therapy

The collaboration will develop Adaptimmune’s SPEAR T-cells in combination with Noile-Immune’s PRIME (IL-7 and CCL19) technology to improve proliferation and trafficking of T-cells to tackle solid tumors The collaboration will develop Adaptimmune’s SPEAR T-cells in combination with Noile-Immune’s PRIME (IL-7 and CCL19) technology to improve proliferation and trafficking of T-cells to tackle solid tumors

Adaptimmune and Noile-Immune Announce Agreement to Develop SPEAR T-Cell Products expressing IL-7 and CCL19 as a next-generation treatment for cancer patients

Adaptimmune Therapeutics plc (ADAP) CEO James Noble on Q2 2019 Results - Earnings Call Transcript

Adaptimmune Therapeutics PLC (ADAP) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Adaptimmune Therapeutics PLC (ADAP) Upgraded to Strong Buy: Here's Why

Cloudera

Falcon Minerals Corp

Kindred Biosciences

Zynga

While most of Wall Street focuses on large and mega cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.

News for Adaptimmune Therapeutics Stock (ADAP)